When our founding Scientific Director Dr. Jim Wright started the Therapeutics Letter in 1994, our goals included relevance to practicing clinicians, accuracy, brevity, and critical analysis of information that was not easily available elsewhere. Over...
Dopamine receptor antagonists are a broad class of drugs characterized by their ability to interfere with the natural actions of the neurotransmitter dopamine, typically in brain, but also in the anterior pituitary where dopamine suppresses...
Bringing Best Evidence to Clinicians: Saturday, October 15, 2022 from 08:30-12:20 h, PDT Have you ever considered participating in one of the TI’s annual courses? This year we are presenting our popular Best Evidence course only online, since...
On September 14, 2022 the University of British Columbia’s Therapeutics Initiative, an academic service that provides unbiased evidence about drug therapy to prescribers and pharmacists, released its latest Therapeutics Letter (issue 138) on “Reducing prescribing cascades”. The authors...